These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Macrophage Membrane-Encapsulated Dopamine-Modified Poly Cyclodextrin Multifunctional Biomimetic Nanoparticles for Atherosclerosis Therapy. Zhu L; Zhong Y; Yan M; Ni S; Zhao X; Wu S; Wang G; Zhang K; Chi Q; Qin X; Li C; Huang X; Wu W ACS Appl Mater Interfaces; 2024 Jun; 16(25):32027-32044. PubMed ID: 38867426 [TBL] [Abstract][Full Text] [Related]
23. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Momi S; Monopoli A; Alberti PF; Falcinelli E; Corazzi T; Conti V; Miglietta D; Ongini E; Minuz P; Gresele P Cardiovasc Res; 2012 Jun; 94(3):428-38. PubMed ID: 22362817 [TBL] [Abstract][Full Text] [Related]
24. [Anti-atherosclerotic effect of pioglitazone--the first evidence of the role of triglyceride/HDL ratio]. Császár A Lege Artis Med; 2011 Feb; 21(2):105-11. PubMed ID: 21710708 [TBL] [Abstract][Full Text] [Related]
25. Macrophage Phenotype and Function in Different Stages of Atherosclerosis. Tabas I; Bornfeldt KE Circ Res; 2016 Feb; 118(4):653-67. PubMed ID: 26892964 [TBL] [Abstract][Full Text] [Related]
26. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. Giannarelli C; Cimmino G; Connolly TM; Ibanez B; Ruiz JM; Alique M; Zafar MU; Fuster V; Feuerstein G; Badimon JJ Eur Heart J; 2012 Jan; 33(2):264-73. PubMed ID: 21606082 [TBL] [Abstract][Full Text] [Related]
27. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice. Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158 [TBL] [Abstract][Full Text] [Related]
28. Effect of Si-Miao-Yong-An on the stability of atherosclerotic plaque in a diet-induced rabbit model. Peng L; Li M; Xu YZ; Zhang GY; Yang C; Zhou YN; Li LJ; Zhang JP J Ethnopharmacol; 2012 Aug; 143(1):241-8. PubMed ID: 22750436 [TBL] [Abstract][Full Text] [Related]
29. Pycnogenol attenuates atherosclerosis by regulating lipid metabolism through the TLR4-NF-κB pathway. Luo H; Wang J; Qiao C; Ma N; Liu D; Zhang W Exp Mol Med; 2015 Oct; 47(10):e191. PubMed ID: 26492950 [TBL] [Abstract][Full Text] [Related]
31. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease. Maranhão RC; Leite AC Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729 [TBL] [Abstract][Full Text] [Related]
32. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571 [TBL] [Abstract][Full Text] [Related]
33. [Cultured cell systems for revelation of new drugs antiatherosclerotic effects and their mechanisms investigation]. Orekhov AN; Sobenin IA; Orekhova VA; Mel'nichenko AA; Miasoedova VA; Mukhamedova NM; Martirosian DM; Pshezhetskiĭ AV; Karagodin VP Patol Fiziol Eksp Ter; 2012; (1):33-9. PubMed ID: 22629858 [TBL] [Abstract][Full Text] [Related]